BioSpace News Archive

Lineage Cell Therapeutics, Inc. (NYSE American and TASE: LCTX), a clinical-stage biotechnology company developing allogeneic cell therapies for unmet medical needs, today reported financial and operating results for the second quarter 2021.

In consideration for its services, Therma Bright will issue up to 800,000 warrants, in tranches, upon certain milestones being met.

SELLAS Life Sciences Group, Inc., a late-stage clinical biopharmaceutical company focused on developing novel cancer immunotherapies for a broad range of indications, reported its financial results for the quarter ended June 30, 2021 and provided a business update.

VistaGen Therapeutics, Inc. (NASDAQ: VTGN), a biopharmaceutical company committed to developing and commercializing a new generation of medicines with the potential to go beyond the current standard of care for anxiety, depression and other central nervous system (CNS) disorders, today reported financial results for its fiscal year 2022 first quarter ended June 30, 2021 and provided a corporate update.

Molecular Templates, Inc. (Nasdaq: MTEM, “Molecular Templates,” or “MTEM”), a clinical-stage biopharmaceutical company focused on the discovery and development of proprietary targeted biologic therapeutics, engineered toxin bodies (ETBs), today reported financial results for the second quarter of 2021.

Today, the American Diabetes Association® and 14 other leading voluntary health organizations and medical societies concerned with diabetes urged the Centers for Disease Control and Prevention (CDC) to consider the health risks people with diabetes are facing with COVID-19 as the agency develops guidance on special patient populations who may benefit from additional COVID-19 vaccine doses

The report highlights trends prevailing in the global respiratory ventilator tester market, and the drivers and restraints pertaining to the market growth.

HAGAR, the developer of GWave, the world’s first non-invasive continuous glucose monitoring technology that uses RF waves to measure glucose levels in the blood, today announced an $11.7 million Series B funding round led by a returning investor, Columbia Pacific.

The market is estimated to grow at a CAGR of 4.8% from 2020 to 2027.

Salarius Pharmaceuticals, Inc. (Nasdaq: SLRX), a clinical-stage biopharmaceutical company developing potential new medicines for patients with sarcomas, pediatric cancers, and other hematologic and solid tumors, announced today that David Arthur, Chief Executive Officer, will present virtually at the Diamond Equity Research Emerging Growth Invitational Conference on Tuesday, August 17, 2021,